Cogent Biosciences (COGT) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Cogent Biosciences (COGT) over the past year, gaining 98.6% versus a gain of 93.1%. Over five years, COGT leads with a +225.5% price change compared with +112.4% for TVTX. Cogent Biosciences is the larger company by market cap ($5.37 billion vs $4.95 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | TVTX |
|---|---|---|
| Share price | $30.95 | $52.47 |
| Market cap | $5.37B | $4.95B |
| 1-day change | +2.89% | +0.83% |
| YTD return | -15.32% | +36.19% |
| 1-year return | +93.07% | +98.63% |
| 5-year return | +225.54% | +112.41% |
| Forward P/E | — | 9.31 |
| EPS (TTM) | $-2.16 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $490.73M |
| Revenue growth (YoY) | — | +110.45% |
| Net income (latest FY) | $-328.94M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | — | -12.80% |
| Net margin | — | -5.21% |
| 52-week high | $43.73 | $68.73 |
| 52-week low | $13.78 | $22.59 |
| Distance from 52-week high | -29.22% | -23.66% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +80.36% | +43.34% |
| Average volume | 1.90M | 1.59M |
| Shares outstanding | 173.52M | 94.26M |
| Employees | 258 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
COGT vs TVTX FAQ
Which is bigger, Cogent Biosciences or Travere Therapeutics?
Cogent Biosciences (COGT) is larger, with a market capitalization of $5.37B compared with $4.95B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, COGT or TVTX?
TVTX returned +98.63% over the past 12 months, compared with +93.07% for COGT (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.